Nasdaq Inc (NDAQ)vsNovo Nordisk A/S (NVO)
NDAQ
Nasdaq Inc
$83.74
-0.64%
FINANCIAL SERVICES · Cap: $49.33B
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 5788% more annual revenue ($309.06B vs $5.25B). NDAQ leads profitability with a 34.1% profit margin vs 33.1%. NDAQ appears more attractively valued with a PEG of 2.10. NDAQ earns a higher WallStSmart Score of 69/100 (B-).
NDAQ
Strong Buy69
out of 100
Grade: B-
NVO
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.4%
Fair Value
$144.61
Current Price
$83.74
$60.87 discount
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 47.6%
Earnings expanding 47.6% YoY
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : NDAQ
The strongest argument for NDAQ centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 34.1% and operating margin at 47.6%. Revenue growth of 13.4% demonstrates continued momentum.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bear Case : NDAQ
The primary concerns for NDAQ are PEG Ratio, P/E Ratio.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
NDAQ profiles as a mature stock while NVO is a declining play — different risk/reward profiles.
NDAQ carries more volatility with a beta of 1.03 — expect wider price swings.
NDAQ is growing revenue faster at 13.4% — sustainability is the question.
NDAQ generates stronger free cash flow (536M), providing more financial flexibility.
Bottom Line
NDAQ scores higher overall (69/100 vs 55/100), backed by strong 34.1% margins and 13.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nasdaq Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
Nasdaq, Inc. is an American multinational financial services corporation that owns and operates stock exchanges in the United States and Europe. It is headquartered in New York City.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other FINANCIAL DATA & STOCK EXCHANGES Stocks
Want to dig deeper into these stocks?